Regulatory context

Not approved, and in regulatory limbo

Dihexa is not approved for any use in any country. In the United States it entered a specific limbo in 2026: removed from the 503A compounding Category 2 list and scheduled for advisory-committee review, which is not the same as approval.

This unit maps the global status, explains what the 503A change does and does not mean, covers anti-doping, and compares dihexa honestly against the approved options it is marketed alongside. Status statements are timestamped to 2026.